THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title: Atomoxetine Tolerability in Patients Receiving Different Dosing Strategies

Author(s): Linda A. Wietecha, MSc; Dustin D. Ruff, PhD; Albert J. Allen, MD, PhD; Laurence L. Greenhill, MD; and Jeffrey H. Newcorn, MD

DOI Number: 10.4088/JCP.12m07991

List of Supplementary Material for the article

1. eTable 1 Time Course of Treatment-Emergent Adverse Events: Prior Stimulant use versus Stimulant Naïveté

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2013 Physicians Postgraduate Press, Inc.

© 2013 COPYRIGHT PHYSICIANS POSTGRADUATE PRESS, INC. NOT FOR DISTRIBUTION, DISPLAY, OR COMMERCIAL PURPOSES.

Supplementary eTable 1. Time Course of Treatment-Emergent Adverse Events: Prior Stimulant use versus Stimulant Naïveté

	Time-to-Onset (Days)				Time After Onset to Resolution (Days)			
Pediatric Patients	**N**	**Median**	**Range**	***P*-Value**	**N**	**Median**	**Range**	***P*-Value**
Abdominal pain								
Prior use	220	11.0	1-69	.171	200	1.0	0-200	.978
Never used	259	8.0	1-85		240	1.0	0-373	
Decreased appetite								
Prior use	189	7.0	1-94	.495	133	26.0	1-337	.877
Never used	281	9.0	1-118		194	22.0	1-891	
Fatigue								
Prior use	101	3.0	1-56	.692	82	12.5	1-300	.653
Never used	115	3.0	1-68		83	11.0	1-532	
Nausea								
Prior use	134	12.0	1-95	.054	126	2.0	1-91	.001
Never used	144	6.0	1-80		133	3.0	1-532	
Somnolence								
Prior use	118	1.0	1-81	.022	97	7.0	0-286	.272
Never used	135	3.0	1-93		117	10.0	0-421	
Vomiting								
Prior use	143	21.0	1-79	.271	140	1.0	1-27	.163
Never used	147	18.0	1-99		145	1.0	1-320	
	Time-to-Onset (Days)				**Time After Onset to Resolution (Days)**			
Adult Patients	**N**	**Median**	**Range**	***P*-Value**	**N**	**Median**	**Range**	***P*-Value**
Nausea								
Prior use	60	8.0	1-103	.212	50	12.0	1-159	.471
Never used	163	3.0	1-198		133	15.0	1-309	
Insomnia								
Prior use	45	7.0	1-150	.810	34	15.5	1-119	.164
Never used	90	6.5	1-193		67	28.0	1-182	
Decreased appetite								
Prior use	18	4.5	1-48	.147	11	19.0	4-210	.316
Never used	66	2.0	1-148		35	40.0	1-270	
Urinary hesitation and/or urinary retention								
Prior use	11	3.0	1-66	.961	6	11.0	2-312	.438
Never used	27	4.0	1-58		13	36.0	3-130	
Fatigue								
Prior use	27	5.0	1-62	.258	13	16.0	3-113	.050
Never used	64	12.5	1-145		41	29.0	1-226	

Abbreviations: N = total number of participants.

© 2013 COPYRIGHT PHYSICIANS POSTGRADUATE PRESS, INC. NOT FOR DISTRIBUTION, DISPLAY, OR COMMERCIAL PURPOSES.